Global RNA Vaccines Market Size By Type (Infectious Disease Treatment RNA Vaccine, Infection Prevention RNA Vaccine), By Application (Cancer Immunotherapy, Allergy Tolerization), By Geographic Scope And Forecast

RNA Vaccines Market Size And Forecast

RNA Vaccines Market size is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2022 to 2030.

One of the major factors driving the market growth is the increasing prevalence of chronic and infectious diseases such as diabetes, HIV, cancer, and CVDs. The market is being driven by the increasing need for therapeutic medications and vaccines for Ebola, HIV, influenza, and other viral illnesses, as well as the traditional vaccination approach’s inability to find vaccines at cheap rates at important moments. In comparison to conventional medicines, RNA vaccines and Therapeutics are developed using advanced technologies that are more effective against pathogens, have higher efficacy, improved immunogenicity, and are less expensive to produce. Furthermore, advancements in lipid nanoparticle formulations for in-vivo systemic RNA delivery are creating a positive outlook for market growth.

Global RNA Vaccines Market Definition

A vaccine is a biological compound that promotes active acquired immunity against a specific infectious disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is frequently composed of weakened or killed versions of the microbe, its toxins, or one of its surface proteins. The agent stimulates the immune system to recognize and destroy the agent as a threat, as well as any microorganisms associated with that agent that it may encounter in the future. Vaccines can be either preventative or therapeutic. Some vaccines provide complete sterilizing immunity, which means the infection is avoided entirely.

An RNA vaccine is a type of vaccine that produces an immune response by using a copy of a molecule known as messenger RNA (RNA). The vaccine introduces antigen-encoding RNA molecules into immune cells, which use the designed RNA as a blueprint to construct a foreign protein that would normally be produced by a cancer cell or a pathogen. These protein molecules activate an adaptive immune response, instructing the body to recognize and destroy the corresponding pathogen or cancer cells.

The RNA is delivered via a co-formulation of RNA encapsulated in lipid nanoparticles, which protect the RNA strands and aid in their absorption into cells. Because RNA plays such an important role in protein expression, RNA technology has a wide range of applications in disease treatment and prevention. Other applications are the treatment of lung and liver diseases and oncological treatment.

Global RNA Vaccines Market Overview

The following factors are contributing to the growth of the RNA Vaccines MarketThe increasing prevalence of emerging and re-emerging infectious diseases, increased emphasis on immunization programs Increasing government support for vaccine development, expanding industry initiatives to improve vaccine research and development, and advancements in lipid nanoparticle formulations for in-vivo systemic RNA delivery. With people traveling much more frequently and over much greater distances than in the past, living in densely populated areas, and coming into closer contact with wild animals, the potential for emerging infectious diseases to spread quickly and cause global epidemics is a major concern.

Furthermore, diseases could emerge as a result of the deliberate introduction into human, animal, or plant populations for terrorist purposes. Anthrax, smallpox, and tularemia are examples of these diseases. Around 40 infectious diseases have been discovered since the 1970s, including SARS, MERS, Ebola, chikungunya, avian flu, swine flu, Zika, and, most recently, COVID-19, which is caused by a new coronavirus, SARS-CoV-2. Experts have warned of future pandemics and epidemics that could be even deadlier than COVID-19. In the coming years, the rising prevalence of these infectious diseases will ensure a steady and growing demand for vaccines.

Over the past decade, messenger RNA (RNA) has emerged as a potent and flexible platform for the development of novel effective cancer immunotherapies. Advances in non-viral gene delivery technologies, especially the tremendous progress in lipid nanoparticles’ manufacturing, have made possible the implementation of RNA-based antitumor treatments. Several RNA-based immunotherapies have demonstrated antitumor effect in preclinical and clinical studies, and marked successes have been achieved most notably by its implementation in therapeutic vaccines, cytokines therapies, checkpoint blockade and chimeric antigen receptor (CAR) cell therapy.

The logistical challenges associated with RNA vaccines, as well as the high price associated with RNA vaccines, are limiting the market’s growth. Despite the advantages, emerging economies are deterred from adopting RNA vaccines due to potential logistical challenges associated with their supply. Furthermore, the absence of adequate infrastructure with stable ultra-cold temperatures in emerging economies has resulted in the adoption of RNA vaccines being prohibited. If a controlled ultra-low supply chain is not present from the time the vaccine is produced to the start of inoculation, RNA vaccines are highly fragile and can easily denature and destabilize. Whereas, the opportunities for growth of the market can be good growth potential of Emerging markets, emphasizing therapeutic vaccines, and development of Vaccine adjuvants.

Global RNA Vaccines Market Segmentation Analysis

The Global RNA Vaccines Market is Segmented on the basis of Type, Application, and Geography.

RNA Vaccines Market, By Type

• Individualized Cancer Treatment RNA Vaccine
• Infectious Disease Treatment RNA Vaccine
• Infection Prevention RNA Vaccine

Based on Type, the market is segmented into Individualized Cancer Treatment RNA Vaccine, Infectious Disease Treatment RNA Vaccine, and Infection Prevention RNA Vaccine. Infection Prevention RNA vaccines are expected to account for the majority of the market for RNA vaccines. The segment of cancer treatment standardization is expected to contribute the most to market growth. The main reason is the growing number of cancer patients around the world, which necessitates the development of a set of treatment guidelines.

RNA Vaccines Market, By Application

• Cancer Immunotherapy
• Allergy Tolerization
• Therapeutic Vaccines
• Protein Replacement
• Others

Based on Application, the market is bifurcated into Cancer Immunotherapy, Allergy Tolerization, Therapeutic Vaccines, Protein Replacement, and Others.

RNA Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of The World

On the basis of Regional Analysis, the Global RNA Vaccines Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America has the largest share of the RNA Vaccines Market for non-Covid-19 vaccines due to the growing need to develop transformative therapeutics, increasing fund infusions, a favorable regulatory environment, and massively growing attention to establishing precision medicine, among other factors. The rising prevalence of cancer and other diseases among Asia’s developing economies is driving up demand for mRNA vaccines and therapeutics in the region.

Key Players

The “Global RNA Vaccines Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Argos Therapeutics, Inc., Arcturus Therapeutics Inc., BioNTech SE, CureVac AG, Ethris GmbH, GlaxoSmithKline PLC, Moderna Therapeutics Inc., Pfizer Inc, Translate Bio Inc., and Sangamo Therapeutics Inc.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

• In October 2018, Vertex Pharmaceuticals Inc. had already announced a collaboration with a California-based startup to develop treatments for two genetic diseases. Vertex has created cystic fibrosis treatments and is collaborating with other companies.
• In February 2022, Merck KGaA and eTheRNA immunotherapies NV have announced a strategic partnership. The collaboration looked into how eTheRNA’s proprietary mRNA design expertise and LNP-delivery platforms can be applied to disease areas chosen by Merck KGaA, Darmstadt, Germany. As a result of this collaboration,
• In February 2022, Moderna launched clinical trials for an HIV mRNA vaccine in its early stages. Earlier, IAVI and Moderna announced that the first doses of an experimental HIV vaccine antigens clinical trial had been administered. The IAVI G002 Phase I trial is designed to test the hypothesis that sequential administration of HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibodies (bnAb) development.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.